| Literature DB >> 11166584 |
M R Ranson1, S Cheeseman, S White, J Margison.
Abstract
Anthracyclines are amongst the most active drugs in the treatment of breast cancer. Stealth liposomal doxorubicin (Caelyx, Doxil, Alza Pharmaceuticals Inc.) is a promising new agent under investigation for the treatment of breast cancer and other solid tumours. The liposomal encapsulation alters drug pharmacokinetics and leads to a marked change in toxicity profile compared to non-liposomal doxorubicin. The results of recently completed and ongoing clinical trials in breast cancer are reviewed.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11166584 DOI： 10.1016/s1040-8428(00)00107-4
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312